
Volume 9, Supplement 1 (Nov/Dec 2018)
Incidence rates of melanoma continue to climb, and while most patients are diagnosed at an early stage, once metastatic, melanoma remains the most deadly of all the cutaneous malignancies. With the discovery of immune checkpoints and therapies that target the MAPK pathway, patients with metastatic melanoma have new treatment options and renewed hope.
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
November 27, 2018
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
November 27, 2018
Current Issue


Survivorship and Advance Care Planning in Cancer
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
March 17, 2025
Decreasing Pain Intensity in Adult Patients With Cancer Through Music Therapy
Leighann B. Montoya, DNP, APRN, AGPC-BC, Dorothie Durosier Mertilus, PhD, DNP, APRN, AGNP-C
March 17, 2025
Digging into the Cause of Drug-Induced Thrombocytopenia A Case Report
Vivian A. Pham, PharmD, Christopher Selby, PharmD, BCOP
March 17, 2025